Curley, P, Moss, DM, Siccardi, M and Owen, A (2016) Development and Validation of a LC-MS/MS Assay for the Quantification Of Efavirenz In Different Biological Matrices. Bioanalysis, 8 (20). pp. 2125-2134. ISSN 1757-6199

[img] Text
EFV LC_MS Method_Bioanalysis_Resubmission.docx - Accepted Version
Available under License Creative Commons Attribution Non-commercial.

Download (581kB)

Abstract

Aim: The non-nucleoside reverse transcriptase inhibitor efavirenz is one of the most prescribed antiretroviral therapeutics. Efavirenz-containing therapy has become associated with the occurrence of CNS side effects, including sleep disturbances, depression and even psychosis.

Results: The investigation of efavirenz distribution required the development of a versatile and sensitive method. In addition to plasma, quantification was required in brain tissue and phosphate-buffered saline. The assay presented here was linear from 1.9 to 500 ng/ml. Accuracy and precision ranged between 93.7 and 99.5%, and 1.5 and 5.6%, respectively.

Discussion: The method developed here represents a versatile, sensitive and easy-to-use assay. The assay has been applied to in vitro and in vivo samples demonstrating reliable efavirenz quantification in multiple matrices.

Item Type: Article
Additional Information: This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Future Science at http://dx.doi.org/10.4155/bio-2016-0021 - please refer to any applicable terms of use of the publisher.
Uncontrolled Keywords: LC–MS/MS, brain tissue, efavirenz, plasma, protein binding
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Medicine and Health Sciences > School of Pharmacy
Depositing User: Symplectic
Date Deposited: 22 May 2017 08:45
Last Modified: 22 Nov 2018 14:13
URI: http://eprints.keele.ac.uk/id/eprint/2932

Actions (login required)

View Item View Item